Joseph Horrigan - Neuren Pharmaceuticals Insider

Neuren Pharmaceuticals Limited -- USA Stock  

USD 0.08  0.012  13.04%

VP of Clinical Devel. and Medical Affairs

Dr. Joseph Horrigan serves as a Vice President Clinical Development and Medical Affairs of Neuren Pharmaceuticals Limited since August 9, 2012. Dr. Joe Horrigan is a pediatric neuropsychiatrist. Prior to joining Neuren in 2012, Dr. Horrigan served as Assistant Vice President and Head of Medical Research for Autism Speaks, the largest science and advocacy organisation in the US devoted to autism spectrum disorders . In this role he was responsible for developing and implementing a comprehensive strategy in the area of translational medical research in ASD, focusing primarily on Phase IIV clinical trials. Prior to joining Autism Speaks, Dr. Horrigan worked for almost 10 years at GlaxoSmithKline, where he was a Senior Director in the Neurosciences Medicines Development Center. In that capacity, he played a lead role in the development and execution of Phase IIIV clinical development programs across several therapeutic areas in neurology and psychiatry. He also cofounded and led the companywide Medicines for Children Advisory Network at GlaxoSmithKline. Dr. Horrigan is also a Clinical Associate Professor in the Department of Psychiatry at the University of North Carolina at Chapel Hill.
  VP Since 2012      
61 3 9092 0480  http://www.neurenpharma.com

Management Efficiency

The company has return on total asset (ROA) of (106.52) % which means that it has lost $106.52 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (191.38) % meaning that it generated substantial loss on money invested by shareholders.

Entity Summary

Neuren Pharmaceuticals Limited, a biopharmaceutical company, focuses on the development of therapies for brain injury, neurodevelopment, and neurodegenerative disorders. Neuren Pharmaceuticals Limited (NURPF) is traded on OTC Market in USA. It is located in Camberwell, VIC and employs 10 people.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Neuren Pharmaceuticals Limited to your portfolio

Top Management

Neuren Pharmaceuticals Leadership Team
Joseph Horrigan, VP
Larry Glass, CEO
Bruce Hancox, Director
James Shaw, COO
Richard Treagus, Chairman, Ph.D
Trevor Scott, Director, Ph.D
Jon Pilcher, CFO

Stock Performance

Neuren Pharmaceuticals Performance Indicators
Return On Equity(191.38) %
Return On Asset(106.52) %
Operating Margin(802.27) %
Current Valuation129.75 M
Price to Earning(25) times
Price to Book27.5 times
Price to Sales246.18 times
Revenue920.82 K
Gross Profit(11 M)
EBITDA(7.33 M)